TIGIT and neoplasm: A recent in-depth mechanistic study revealed that an anti-TIGIT antibody enhances PD-L1 blockade, facilitating the shift of anti-tumor CD8 + T cells from an exhausted effector-like state to a more memory-like state through myeloid and Treg cells.